最新医学　別冊　新しい診断と治療のABC15　心房細胞

出版社： 最新医学社
発行日： 2003-10-25
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 心房細動
電子書籍版： 2003-10-25
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学 別冊　新しい診断と治療のABC15　心房細胞

    ―目次―

    第１章　心房細動の概念・定義
    　概念・定義-特に心房細動研究の初期から見て-
    　疫学・予後

    第２章　心房細動の病理・病態生理
    　病理
    　発生機序
    　自立神経
    　心房細動と血行動態
    　
    第３章　心房細動の診断
    　診断、検査の進め方
    　ホルター心電図の意義
    　心エコー検査の意義
    　血栓塞栓症のリスク評価
    　
    第４章　心房細動の管理・治療
    　心房細動の管理・治療の進め方
    　薬物治療の考え方
    　I群抗不整脈薬の薬理作用と使い方
    　beta 遮断薬、ｼﾞｷﾀﾘｽ剤、ｶﾙｼｳﾑ拮抗薬の薬理作用と使い方
    　?郡薬（ｱﾐｵﾀﾞﾛﾝ、ｿﾀﾛｰﾙ）とﾍﾞﾌﾟﾘｼﾞﾙの薬理作用と使い方
    　電気的除細動の適応とその実際
    　血栓塞栓症の予防
    　心房細動のカテーテルアブレーション
    　心房粗動のカテーテルアブレーション（ハイブリッド療法）
    　心房細動・粗動のペースメーカー治療
    　心房細動手術の適応と実際
    　QOLの評価とライフスタイルの改善
    　心理療法の適応とその実際
    　孤立性心房細動への対処法
    　高齢者の心房細動の診療
    　心房細動と心不全の管理
    　心房細動と突然死の管理
    　心房細動と医療経済
    　トピックス：心房筋リモデリング
    　トピックス：AFFIR
    　トピックス：植込み型心房除細動器
    　
    第５章　心房細動のガイドライン 　
    　心房細動のガイドライン
    　
    座談会　心房細動の治療の最前線の考え方と実践

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 心房細動の概念・定義

P.15 掲載の参考文献
1) Burch G E, et al:A History of Electrocardiography. Year Book Medical Publichers, Inc, Chicago, 1964.
 
2) Mandel W J:Cardiac Arrhythma-Their mechanisms diagnosis and management (2nd Ed), Lippincott Company, Philadelphia, 1887.
 
3) 早川弘一, 笠貫 宏 編:心室細動・粗動・頻拍. 医学書院, 東京, 1999.
 
P.23 掲載の参考文献
1) Wolf P A, et al:Atrial fibrillation as an independent risk factor for stroke. The Framingham Study. Stroke 22:983-988, 1991.
PubMed
2) Kannel W B, et al:Coronary heart disease and atrial fibrillation:The Framingham Study. Am Heart J 106:389-396, 1983.
PubMed
3) Feinberg W M, et al:Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 155:469-473, 1995.
PubMed
4) 橋場邦武:老年者の不整脈. 日老医誌 26:101-110, 1989.
 
5) 藤島正敏:脳血管障害のリスクファクターとしての心疾患. 循環器医 6:19-26, 1998.
 
6) 新博次, 他:一般総合病院における不整脈出現頻度-高年齢群の特徴-. 日老医誌 23:41-49, 1986.
 
7) Wolf P A, et al:Secular trends in the prevalence of atrial fibrillation:The Framingham Study. Am Heart J 131:790-795, 1996.
PubMed
8) Levy S, et al:Characterization of different subsets of atrial fibrillation in general practice in France. The ALFA Study. Circulation 99:3028-3035, 1999.
PubMed
9) Tomita F, et al:Prevalence and clinical characteristics of patients with atrial fibrillation:Analysis of 20, 000 cases in Japan. Jpn Circ J 64:653-658 2000.
PubMed
10) Benjamin E J, et al:Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation 98:946-952, 1998
PubMed
11) Vidaillet H, et al:Apopulation-based study of mortality among patients with atrial fibrillation or flutter Am J Med 113:365-370, 2002.
PubMed
12) Krahn A D, et al:The natural history of atrial fibrillation:Incidence, risk factors, and prognosis in the Manitoba Follow-up Study. Am J Med 98:476-484, 1995.
PubMed
13) Kopecky S L, et al:The natural history of lone atrial Fibrillation. A population-based study over three decades. N Engl J Med 317:669-674, 1987.
PubMed
14) Scardi S, et al:Lone atrial fibrillation:Prognostic differences between paroxysmal and chronic forms after 10 years of follow-up. Am Heart J 137:686-691, 1999.
PubMed
15) Gajewski J, et al:Mortality in an insured population with atrial Fibrillation. JAMA 245:1540-1544, 1981.
 
16) Goldberg RJ, et al:Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction:A community-wide perspective. Am Heart J 119:996-1001, 1990.
PubMed
17) Crenshaw B S, et al:Atrial fibrillation in the setting of acute myocardial infarction:The GUSTO-I Experience. J Am Coll Cardiol 30:406-413, 1997.
PubMed
18) Wong C K, et al:New atrial fibrillation after acute myocardial infarction independently predicts death:The GUSTO-III experience. Am Heart J 140:878-885, 2000.
PubMed

第2章 心房細動の病理・病態生理

P.31 掲載の参考文献
1) Bharati S, et al:Histology of the normal and diseased atrium. In:Atrial Fibrillation:Mechanisms and Management (Falk R H, et al, eds). p15-39. Raven Press, New York, 1992.
 
2) Feinberg W M, et al:Prevalence, age distribution, and gender of patients with atrial Fibrillation. Arch Intern Med 155:469-473, 1995.
PubMed
3) Falk R H:Etiology and complications of atrial fibrillation:insights from pathology studies. Am J Cardiol 82 (8A):10N-17N, 1998.
PubMed
4) Daoud E G, et al:Pathophysiology of atrial flutter. Annu Rev 49:77-83, 1998.
PubMed
5) Goddtfredsen J:Physiology and pathophysiology of the atria:its role in atrial fibrillation. J Thromb Thrombolysis 7:13-19, 1999.
PubMed
6) Brugada R, et al:Molecular biology and atrial fibrillation. Curr Opin Cardiol 14:269-273, 1999.
PubMed
7) Haissagurre M, et al Spontaneous initiation of atrial fibrillation by ectopoic beats originating pulrnonary veins N Engl J Med 339 659-666, 1998.
 
8) Saito T, et al:Left atrial myocardial extension onto pulmonary veins in humans:anatomic observations relevant for atrial arrhythmias. J Cardiovasc Electrophysiol 11:888-894, 2000.
PubMed
9) Hashizume H, et al:A histological study of the cardiac muscle of the human superior and inferior venae cavae. Arch Histol Cytol 58:457-464, 1995.
PubMed
10) Masani F:Node-like cells in the myocardial layer of the pulmonary vein of rats:an ultrastructural study. J Anat 145:133-142, 1986.
PubMed
11) Schwartzman D:Right pulmonary vein potentials recorded from the posterior right atrial endocardium:human case report and validation in a porcine model J Cardiovasc Electrophysiol 11:330-333, 2000.
 
12) Dean J W, et al:Clinical anatomy of the atrioventricular junctions. J Am Coll Cardiol 24:1725-1731, 1994.
PubMed
13) Anderson RH, et al:The anatomy of the heart revisited. Anat Rec 246:1-7, 1996.
PubMed
14) Cabrera J A, et al:The architecture of the atrial musculature between the orifice of the inferior caval vein and the tricuspid valve:the anatomy of the isthmus. J Cardiovasc Electrophysiol 9:1186-1195, 1998.
PubMed
15) Cosio F G, et al:ESCWGA/NASPE/P Experts Consensus Statement:Living anatomy of the atrioventricular junctions. A guide to electrophysiologic mapping. Working Group of Arrhythmias of the European Society of Cardiology. North American Society of Pacing and Electrophysiology. J Cardiovasc Electrophysiol 10:1162-1170, 1999.
 
16) 河合祥雄, 他:心房細動の病理. J Cardiol 33 (Supple 1):47-52, 1999.
 
17) Koch W:Uber das Ultimum moriens des menschlichen Herzens. Beitrage zur pathologischen Anatomie und zur allegemeine Pathologie 42:203-224, 1907.
 
18) Domenech-Mateu J M, et al:Development of the tendon of Todaro during the human embryonic and fetal periods. Anat Rec 238:374-382, 1994.
PubMed
19) Kozlowski D, et al:Morphology of the tendon of Todaro Within the human heart in ontogenesis Folia Morphol (Warsz) 59:201-206, 2000.
PubMed
20) Ausma J, et al:Differentiation of atrial cardiomyocytes as a results of chronic atrial fibrillation. Am J Pathol 151:985-997, 1997.
PubMed
21) Sugiura M, et al:A Clinicopathological study on sick sinus syndrome with histological approach to the sinotrial node Jpn Circ J 44:497-504, 1980.
 
22) Fujino M, et al:The relationship of aging histological changes in the conduction system of the normal human heart Jpn Heart J 24:13-20, 1983.
PubMed
23) Triposkiadis F, et al:Left atrial myopathyin idiopathic dilated cardiomyopathy. Am Heart J 128:308-315, 1994.
 
24) Frustaci A, et al:Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96:1180-1184, 1997.
PubMed
25) Davies M J, et al:Pathology of atrial fibrillation in man. Br Heart J 34:520-525, 1972.
PubMed
26) Ih S, et al:The histopathological substratum for atrial fibrillation in man. Acta Pathol Jpn 32:183-191, 1982.
PubMed
27) 大川真一郎:不整脈の臨床と病理-刺激伝導系の病理を中心に-. 不整脈 16:312-329, 2000.
 
28) Goette A, et al:Calpins and cytokines in fibrillating human atria. Am J Physiol Heart Circ Physiol 283:H264-272, 2002.
 
29) Wijffels M C, et al:Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92:1954-1968, 1995.
PubMed
P.38 掲載の参考文献
1) Garrey W E:Auricullar fibrillation. Physiol Rev 215:215-224, 1924.
 
2) Lewis T, et al:Observations upon flutter and fibrillation. Part II:The nature of auricular flutter. Heart 7:191-246, 1920.
 
3) Scherf D, et al:Experimental studies on auricullar flutter and auricular fibrillation. Am Heart J 36:241-251, 1948.
 
4) Sano T, et al:Multiple recordings during electrically induced atrial fibrillation. Circ Res 14:117-125, 1964
PubMed
5) Moe G K, et al:A computer model of atrial fibrillation. Am Heart J 67:200-220, 1964.
PubMed
6) Allessie M A, et al:Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. Theleading circle"concept:a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res 41:9-18, 1977.
 
7) Li D, et al:Ionic mechanism of repolarization differences between canine right and left atrium. Circ Res 88:1168-1175, 2001.
PubMed
8) Allessie M A, et al:Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation. In:Cardiac Arrhythmias (Zipes D P, et al, eds). p265-276, Grune & Stratton, New York, 1985.
 
9) Cox J L, et al:The surgical treatment of atrial fibrillation. II:Intraoperative electrophysiologic mapping and description of the electrophysiological basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 101:406-426, 1991.
PubMed
10) Konings K T S, et al:High density mapping of electrically induced atrial fibrillation in man. Circulation 89:1665-1680, 1994.
 
11) Mandapati R, et al:Stable microrenetrant sourcesa as a mechanism of atrial fibrillation in the isolated sheep heart Circulation 101:194-199, 2000.
 
12) Davidenko J M, et al:Stationary and drifting spiral waves of excitation in isolated cardiac muscle. Nature 355:349-351, 1992.
PubMed
13) Kneller J, et al:Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properdes. Circ res 90:E73-E87, 2002.
 
14) Ikeda T, et al:Mechanism of spontaneous termination of functional reentry in isolated canine right atrium. Evidence for the presence of an excitable but nonexcited core. Circulation 94:1962-1973, 1996.
PubMed
15) Haissaguerre M, et al:Spontaneous initiation of atrial fibrillation by ectopic beats originating from pulmonary veins. N Engl J Med 339:659-666, 1998.
PubMed
16) Wijffels M C E F, et al:Atrial fibrillation begets atrial fibrillation:a study in awake chronically instrumented goats. Circulation 92:1954-1968, 1995.
 
17) Leistad E, et al:Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by Bay K 8644. Circulation 93:1747-1754, 1996.
PubMed
18) Van Wagoner D R et al:Outward K? current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 80:772-781, 1997.
PubMed
19) Yue L, et al:Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 81:512-525, 1997.
 
20) Gaspo R et al:Tachycardia-induced changesin Na? current in a chronic dog model of atrial fibrillation. Circ Res 81:1045-1052, 1997.
 
21) van der Velden H M, et al:Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat Cardiovasc Res 46:476-486, 2000.
PubMed
22) Chen Y H, et al:KCNQ1 gain-of-function mutation in familiar atrial fibrillation, Science 299:251-254, 2003.
 
P.47 掲載の参考文献
1) Hurne J R et al:Ionic basis of the different action potential configurations of single guinea-pig atrial and ventricular myccytes J physiol 368:525-544, 1985.
 
2) Sakmann B, et al Acetylcholine activation of single muscarinic K? channels in isolated pacemaker cells of the mammalian heart. Nature 303:250-253, 1983.
PubMed
3) Iijima T, et al:Membrane currents and their modification by acetylcholine in isolated single atrial cells of the guinea-pig. J physiol 359:485-501, 1985.
PubMed
4) Horie M, et a:Rectification of muscarinic K current by magnesium ion in guinea pig atrial cells. Am J Physiol 253:H210-H214, 1987.
 
5) Chen Y H, et al:KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299:251-254, 2003.
PubMed
6) Brugada R, et a:Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 336:905-911, 1997
PubMed
7) Brugada P, et al:Right bundle branch block persistent ST segment elevation and sudden cardiac death:a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 20:1391-1396, 1992.
PubMed
8) Morita H et al:Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol 40:1437-1444, 2002.
PubMed
9) Chen Q, et al:Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392:293-296, 1998.
PubMed
10) Yan G X, et al Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 100:1660-1666, 1999.
PubMed
11) Donahue J K, et al:Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med 6:1395-1398, 2000.
PubMed
12) Coumel P:Autonomic arrhythmogenic factors in paroxysmal atrial fibrillation. In:Atrial fibrillation:Mechanisms and therapeutic strategies, p171-185. Futura Publishing Co., Armonk, 1994.
 
13) Zipes D P, et al:Nervous conrol in Cardiac Electrophysiology, p411-465. Saunders Pub. Philadelphia 1995.
 
14) 井上 博:心房細動と自律神経, 心房細動・粗動・頻拍, p36-41. 医学書院, 東京, 1999.
 
P.53 掲載の参考文献
1) White C W, et al:Effects of acute atrial fibrillation on the vasodilator reserve of canine atrium. Cardiovasc Res 20:683-689, 1986.
PubMed
2) Upshaw C B Jr:Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Intern Med 157:1070-1076, 1997.
PubMed
3) Doud E G et al:Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 78:1433-1436, 1996.
 
4) Clark D M et al:Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 30:1039-1045, 1997.
PubMed
5) Heinz G et al:Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recent atrial flutter. Am J Cardiol 69:489-492, 1992.
 
6) Goette A, et al:Electrical remodellig in atrial fibrination:time course and mechanisms. Circulation 94:2968-2974, 1996.
 
7) Lehman G, et al:Atrial mechanical performance after internal and external cardioversion of atrial fibration:an echocardiographic study. Chest 121:13-18, 2002.
 
8) Kahn I A:Atrial stunning determinants and cellular mechanism. Am Heart J 145:787-794, 2003.
 

第3章 心房細動の診断

P.62 掲載の参考文献
1) Fuster V, et al:ACC/AHA/ESC Guideline for the Management of Patients With Atrial Fibrillation:Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferrances Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 104 (17):2118-2150, 2001.
 
2) Black I W, et al:Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation:a multicenter study. Circulation 89:2509-2513, 1994.
PubMed
3) Klein A L, et al:Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344:1411-1420, 2001.
PubMed
4) Zabalgoitia M, et al, for the Stroke Prevention in Atrial Fibrillation studies.:Transesophageal echocardiographic correlates of thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 31:1622-1626, 1998.
PubMed
5) Brignole M, et al:Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation:a randomized controlled study. Circulation 96:2617-2624, 1997.
PubMed
6) Fihn S D, et al, for the National Consortium of Anticoagulation Clinics.:The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 124:970-979, 1996.
PubMed
7) Paterson P, et al:Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications inchronic atrial fibrillation:the Copenhagen AFASAK study. Lancet 1:175-179, 1989.
 
P.77 掲載の参考文献
1) Anderson J L, et al:Prevention of symptomatic recurrence pf paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 80:1557-1570, 1989.
 
2) Bhandari A K, et al:Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibbrillation:A transtelephonic monitoring study. Am Heart J 124:381-386, 1992.
 
3) Lee S H, et al:Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation:a double-blind, randomized trial. J Intern Med 239 253-260, 1996.
 
4) Turazza F M, et al:Is anticoagulation therapy underused in elderly patients with atrial fibrillation? Drugs Aging 10:174-184, 1997.
PubMed
5) Atrial Fibrillation Investigaors:Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation:analysis of pooled data from five randomized controned trials. Arch Intern Med 154:1449-1457, 1994.
 
6) 青崎正彦:塞栓症のリスクをどう見分けるか. Heart View:436-442, 1997.
 
7) Pengelly C D:Alcohol and paroxysmal atrial fibrillation[letter]. Int J Clin Pract 51:416, 1997.
PubMed
8) Coumel P:Autonomic arrhythmogenic factors in paroxysmal atrial fibrillation. In:Atrial Fibrillation Mechanisms and Therapeutic Strategies (Olsson S B, et al, eds). p171-185 Futura Publishing Co, Armonk, 1994.
 
9) Haissaguerre M, et al:Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J med 339:659-666, 1998.
PubMed
10) Haissaguerre M, et al:Electrophysiological endopoint for catheter ablation of atrial fibrillation initiated from multiple pulmonaryvenous foci. Circulation 101:1409-1417, 2000.
 
11) 熊谷浩一郎:心房細動とアブレーション. 不整脈 2001. p100-109. メデイカルレビュー社, 東京, 2001.
 
P.86 掲載の参考文献
1) Chugh S S, et al:Epidemiology and natural history of atrial fibrillation:clinical implications J Am Coll Cardiol 37 (2):371-378, 2001.
PubMed
2) Vaziri S M, et al:Echocardiographic predictors of nonrheumatic atrial fibrillation:The Framingham Heart Study. Circulation 89 (2):724-730, 1994.
PubMed
3) Grogan M, et al:Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 69 (19):1570-1573, 1992.
 
4) The Stroke Prevention in Atrial Fibrillation Investigators:Predictors of thromboembolism in atrial fibrillation:II. Echocardiographic features of patients at risk. Ann Intern Med 116 (1):6-12, 1992.
PubMed
5) Petersen P:Thromboembolic complications in atrial fibrillation. Stroke 21 (1):4-13, 1990.
PubMed
6) Wolf P A, et al:Atrial fibrillation as an independent risk factor for stroke:the Framingham Study. Stroke 22 (8):983-988, 1991.
PubMed
7) Beppu S, et al:Smoke-like echo in the left atrial cavity in mitral valve disease:its features and significance. J Am Coll Cardiol 6 (4):744-749, 1985.
PubMed
8) Hart R G, et al:Atrial fibrillation and stroke:concepts and controversies. Stroke 32 (3):803-808, 2001.
PubMed
9) Oh J K:Transesophageal Echocardiography. In:The Echo Manual. 2nd ed. p21-36, Lippincott-Raven, 1999.
 
10) Zabalgoitia M, et al:Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 31 (7) 1622-1666, 1998.
PubMed
11) The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography:Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 128 (8):639-647, 1998.
PubMed
12) Black I W, et al:Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 21 (2):451-457, 1993.
PubMed
13) Chimowitz M L et al:Left atrial spontaneous echo contrast is highly associated with previous stroke in patients with atrial fibrillation or mitral stenosis. Stroke 24 (7):1015-1019, 1993.
PubMed
14) Mugge A, et al:Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with non-rheumatic atrial fibrillation:identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol 23 (3):599-607, 1994.
 
15) Tunick P A, et al:Protruding atheromas in the thoracic aorta and systemic embolization. Ann Intern Med 115 (6):423-427, 1991.
PubMed
16) Amarenco P, et al:Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 331 (22):1474-1479, 1994.
PubMed
17) Di Tullio M R, et al:Aortic atheromas and acute ischemic stroke:a transesophageal echocardiographic study in an ethnically mixed population. Neurology 46 (6):1560-1566, 1996.
 
18) Homma S, et al:Characteristics of patent foremen ovale associated with cryptogenic stroke:a biplane transesophageal echocardiography study. Stroke 25 (3):582-586, 1994.
 
19) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Circulation 104 (17):2118-2150, 2001.
PubMed
20) Klein A L, et al:Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344 (19):1411-1420, 2001.
 
21) Sugioka K, et al:Impact of aortic stiffness on ischemic stroke in eldely patients. Stroke 33 (8):2077-2081, 2002.
 
22) Di Tullio M R, et al:Aortic atheroma morphology and the risk of ischemic stroke in a multiethnic population. Am Heart J 139 (2 pt 1):329-336, 2000.
 
P.97 掲載の参考文献
1) Albers G W:Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med 154:1443-1448, 1994.
PubMed
2) Atrial Fibrillation Investigators:Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449-1457, 1994.
 
3) 青崎正彦:塞栓症のリスクをどう見分けるか. Heart View 1:436-442, 1997.
 
4) Hart R G, et al:Atrial fibrillation and thromboembolism:a decade of progress in stroke prevention. Ann Intern Med 131:688-695, 1999.
PubMed
5) Hart R G, et al:Factors associated with ischemic stroke during aspirn therapy in atrial fibrillation. Analysis of 2012 participants in the SPAFI-III clinical trials. Stroke 30:1223-1229, 1999.
 
6) Fuster V, et al:ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation:executive summary:areport of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Circulation 104:2118-2150, 2001.
 
7) Albers G W, et al:Antithrombotic therapy in atrial fibrillation. Chest 119:194S-206S, 2001.
PubMed
8) Hart R G, et al:Atrial fibrillation and stroke. Concepts and controversies Stroke 32:803-808, 2001.
PubMed
9) Lip G Y H, et al:Antithrombotic therapy for atrial fibrillation. Br Med J 325:1022-1025, 2002.
 
10) Feinberg W M, et al:Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications Arch Intern Med 155:469-473, 1995.
PubMed
11) Albers G W, et al:Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med 115:727-736, 1991.
PubMed
12) Kelley R E:Rationale for antithrombotic therapy in atrial fibrillation. Neurol Cnn 10:233-249, 1992.
 
13) Stein B, et al:Should patients with atrial fibrillation be anticoagulated prior to and chronically following cardioversion? Cardiovasc Clin 21:231-247, 248-249, 1990.
 
14) Atrial Fibrillation Investigators:Echocardiographic predictors of stroke in patients with atrial fibrillation. A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 158:1316-1320, 1998.
 
15) Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography:Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonralvular atrial fibrillation. Ann Intern Med 128:639-647, 1998.
PubMed
16) Lip G Y H, et al:Increased markers of thrombogenesis in chronic atrial fibrillation:affects of warfarin treatment Br Heart J 73:527-533, 1995.
 
17) Lip G Y H:Does atrial fibrillation confer a hypercoagulable state? Lancet 346:1313-1314, 1995.
 
18) Mitusch R, et al:Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticaagulant therapy. Thromb Haemost 75:219-223, 1996.
PubMed
19) Feinberg W M, et al:Markers of thrombin and platelet activity in patients with atrial fibrillation. Correlation with stroke among 1531 participants in the Stroke Prevention in Atrial Fibrillation III study. Stroke 30:2547-2553, 1999.
PubMed
20) Petersen P, et al:Embolic complications in paroxysmal atrial fibrillation. Stroke 17:622-626, 1986.
PubMed
21) 青木 晶, 他:発作性心房細動は脳梗塞発症の危険因子となるか?Jpn Circ J 58 (Suppl 1):327, 1994 (抄録)
 
22) Aboaf A P, et al:Paroxysmal atrial fibrillation. A common but neglected entity. Arch Intern Med 156:362-367, 1996.
PubMed
23) 青崎正彦:心房細動にどこまで抗凝固薬, 抗血小板凝集薬を用いたらよいか? 心臓病の臨床-今日の論点 (木全心一編著), p188-201. 中外医学社, 東京, 1992.
 

第4章 心房細動の管理・治療

P.109 掲載の参考文献
1) AFFIRM investigators:A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825 1833, 2002.
 
2) Van Gelder I C, et al:A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834-1840, 2002.
PubMed
3) Yamashita T, et al:Investigation of the optimal treatment strategy for atrial fibrillation in Japan:The J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) study design. Circ J 67:738-741, 2003.
 
4) Fuster V, et al:ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation:Executive summary. Circulation 104:2118-2150, 2001.
PubMed
5) 外山淳治, 他:心房細動治療(薬物)ガイドライン. Jpn Circ J 65:931-978, 2001.
 
6) 小川 聡:抗不整脈薬ガイドライン. CD-ROM 版ガイドラインの解説とシシリアンガンビットの概念 (抗不整脈薬ガイドライン委員会編). ライフメディコム, 東京, 2000.
 
P.118 掲載の参考文献
1) Li D, et al:Promotion of atrial fibrmation by heart failure in dogs:atrial remodeling of a different sort. Cirulation 100:87-95, 1999.
 
2) Elvan A, et al:Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs:electrophysiological remodeling. Circulation 94:2953-2960, 1996.
PubMed
3) Sticherling C, et al:Effects of digoxim on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation 102:2503-2508, 2000.
PubMed
4) Haissaguerre M, et al:Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659-666, 1998.
PubMed
5) Li D, et al Effects of angiotensm-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104:2608-2614, 2001.
PubMed
6) Pedersen O D, et al:Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:376-380, 1999.
PubMed
7) Pedersen O D, et al:Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function:Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) substudy. Circulation 104:292-296, 2001.
PubMed
8) Nattel S, et al:Ionic remodeling in the heart pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 87:440-447, 2000.
PubMed
9) Faheh S, et al:The T-type Ca channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation 100:2191-2197, 1999.
 
10) Shinagawa K, et al:Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium:insights into the mechanism of the superior efficacy of amiodarone. Circulation 107:1440-1446, 2003.
PubMed
11) Sinno H, et al:Atrial ischemia promotes atrial fibrillation in dogs. Circulation 107:1930-1936, 2003.
PubMed
12) Scheibner A J, et al:Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 142:838-842, 2001.
 
13) Chen Y H, et al:KCNQ1 gainrof-function mutation in familial atrial fibrillation. Science 299:251-254, 2003.
PubMed
14) Kanki H, et al:Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics. Cardiovasc Drugs Ther 12:475-482, 1998.
PubMed
15) Sato T, et al:Electropharmacologic effects of pilsicainide, a pure sodium channel blocker, on the remodeled atrium subjected to chronic rapid pacing. J Cardiovasc Pharmacol 38:812-820, 2001.
PubMed
16) The atial fibrillation follow-up investigation of rhythm management (AFFIRM) investigators. A comparison rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833, 2002.
 
P.125 掲載の参考文献
1) Feinberg M W, et al:Prevalance, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Internal Med 155:469-473, 1995.
 
2) Hart R G, et al:Stroke with intermittent atrial fibrillation:incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 35:183-187, 2000.
PubMed
3) Task Force of the Working Group on Arrhythmias of the European Society of Cardiology:The Sicilian Gambit; Anew approach to the classification of antiarrhythmic drugs based on their action on arrhythmogenic mechanisms. Circulation 84:1831-1851, 1991.
 
4) 心房細動治療(薬物)ガイドライン:Jpn Circ J 65 (Supple V):931-998, 2001.
 
5) 小川聡著:第4章 抗不整脈薬選択の実際・ 2 心房細動. 抗不整脈薬ガイドライン (抗不整脈薬ガイドライン委員会 編), p37-45. ライフメディコム, 東京, 2000.
 
6) Fuster V, et al:ACC/AHA/ESC guidelines for management of the atrail fibrillation:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guideline and the European Society of Cardiac Committee for Practice Guideline and Policy Conferences (Committee to develop Guidelines for the management of Patients With Atrial Fibrillation) Developed in Collabortation With the North American Society of Pacing and Electrophysiology. Circulation 104:2118-2150, 2001.
 
7) Wijffels M C, et al:Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92:1954-1968, 1995.
PubMed
8) Haissaguerre M, et al:Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659-666, 1998.
PubMed
9) Jais P, et al:Distinctive electrophysiological properties of pulmonary veins in patients with atrial fibrillation Circulation 106:2479-2485, 2002.
PubMed
10) Nattel S, et al:Ionic remodeling in the heart pathophysiological significance and new therapeutic opportunities for atrial fibrillation Circ Res 87:440-447, 2000 (review).
PubMed
11) Goette A, et al:Increased expression of extracellular signal-regulated kinase and angiotensint-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35:1669-1677, 2000.
PubMed
12) Pederson O D, et al:Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:376-380, 1999.
 
13) The Cardiac Arrhythmia Suppression Trial (CAST). Preliminary report:Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406-412, 1989.
 
14) 児玉逸雄:抗不整脈薬と Na 電流. 抗不整脈薬の新たな展開 (新博次 編) p42-52. 医薬ジャーナル社, 大阪, 2003.
 
15) 児玉逸雄:ナトリウムチャネル遮断薬の薬理と使い分け. 治療薬 3・4 巻:37-41, 1998.
 
16) Hondeghem L M, et al:Time and voltagedependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochem Biophys Acta 472:373-398, 1977.
PubMed
17) Kodama I, et al:Two types of sodium channel block by class-I antiarrhythmic drugs studied by using V max of action potential in single ventricular myocytes. J Moll Cell Cardiol 22:1-12 1990.
 
P.132 掲載の参考文献
1) 外山淳治:心房細動治療(薬物)ガイドライン. Jpn Circulation J 65 (Suppl. V):931-978, 2001.
 
2) A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Eur European Society of Cardiology Committee for Practice Guidelines and Policy Conferences:ACC/AHA/ESC guidelines for management of patients with atrial fibrillation. J Am Coll Cardiol 38 (1):1231-1265, 2001.
 
3) 小川聡:抗不整脈薬ガイドライン‐CD-ROM 版ガイドラインの解説とシシリアンガンビットの概念. ライフメデイコム, 東京, 2000.
 
4) 早川弘一, 他編:心房細動, 粗動, 頻拍. 医学書院, 東京, 1999.
 
5) Farshi R et al:JVentricular rate control in chronic atrial fibrillation during daily activity and programmed exercise:acrossover open-label study of five drug regimens. J Am Coll Cardiol 33:304-310, 1999.
 
6) Tieleman R G, et al:Early recurrences of atrial fibrillation after electrical cardioversion:a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 31:167-173, 1998.
 
7) Wyse D G, et al:Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833, 2002.
 
P.142 掲載の参考文献
1) Roy D, et al:Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342:913-920, 2000.
PubMed
2) Derakhchan K, et al:The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF. Cardiovasc Res 50:75-84, 2001.
PubMed
3) 児玉逸雄:アミオダロンの基礎‐多彩な標的分子‐. Prog Med 23 (suppl. 1):1292-1302, 2003.
 
4) Kamiya K, et al:Short-amd long-term effects of amiodarone on the two components of cardiac delayed rectifier K? current. Circulation 100:1317-1324, 2001.
 
5) Osaka T, et al:Effects of bepridil on ventricular depolarization and repolarization of rabbit isolated hearts with paticular reference to its possible proarrhythmic properties. Br J Pharmacol 93:775-780, 1988.
 
6) Nose S, et al:Bepridil prolongs the action potential duration of guinea pig ventricular muscle only at rapid rates of stimulation. Gen Pharmac 24:1187-1196, 1993.
 
7) 安田雅之, 他:クラス I 群無効の心房細動および心房粗動に対するベプリジルの有用性. 心電図 23:53-60, 2003.
 
8) Yoshida T, et al:Bepridil prevents paroxysmal atrial fibrillation by a Class III antiarrhythmic drug effect. Pacing Clin Electrophysiol 26 (Pt. II):314-317, 2003.
 
9) Wang J C, et al:Bepridil differentially inhibits two delayed rectifier K? currents, IKr. and Iks, in gunea-pig ventricular myocytes. Br J Pharmacol 128:1733-1738, 1999.
 
10) Hara Y, et al:SD-3212, a new class I and IV antiarrhythmic drug:a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea pig atrial cells. Br J Pharmacol 116:2750-2756, 1995.
 
11) Kobayashi S, et al:Inhibitory effect of Bepridil on hKv1.5 channel current:comparison with amiodarone and E-4031. Eur J Pharmacol 430:149-159, 2001.
 
12) Yatani A, et al:Bepridil block of cardiac calcium and sodium channels. J pharmacol Exp Ther 237:9-17, 1986.
PubMed
13) Osaka T, et al:Supplementary Bepridil potentiates antifibrillatory effects of arniodarone by modulating the frequency-dependence of atrial action potential duration (abst). J Am Coll Cardiol 39:83A, 2002.
 
14) Osaka T, et al:Action potential remodeling in the human right atrium with chronic lone atrial fibrillation. Pacing Clin Electrophysiol 23:960-965, 2000.
PubMed
15) Kumagai K, et al:Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41:2197-2204, 2003.
PubMed
16) Yue L, et al:Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 84:776-784, 1999.
 
17) Fareh S, et al:The T-type Ca?? channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation 100:2191-2197, 1999.
 
18) Shinagawa K, et al:Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium. Insights into the mechanism of the superior efficacy of amiodarone. Circulation 107:1440-1446, 2003.
PubMed
19) Madrid A H, et al:Use of irbesartan to maintain sinus rhythm in patients with long-lasting Persistent atrial fibrillation. A prospective and randomized study. Circulation 106:331-336, 2002.
PubMed
20) Cohen C J, et al:Block of T-type Ca channel in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol 100:703-728, 1992.
PubMed
21) Chugh S S, et al:Amplified effects of d, 1-sotalol in canine dilated cardiomyopathy. Pacing Clin Electrophysiol 24:1783-1788, 2001.
PubMed
P.150 掲載の参考文献
1) 日本循環器学会:心房細動治療(薬物)ガイドライン. Jpn Circ J 65 (suppl V):931-998, 2001.
 
2) Fuster V, et al:ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation:Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 104:2118-2150, 2001.
 
3) Wyse D G, et al:A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347:1825-1833, 2002.
PubMed
4) Van Gelder I C, et al:A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl JMed 347:1834-1840, 2002.
 
5) Arnold A Z, et al:Role of prophylactic anticoagulation for direct current cardioversionin patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 19:851-855, 1992.
PubMed
6) Naccarehi G V, et al:Cost-effective management of acute atrial fibrillation:role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. Am J Cardiol 85:36D-45D, 2000.
 
7) Klein A L, et al:Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation J Am Coll Cardiol 37:691-704, 2001.
PubMed
8) Coplen S E, et al:Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials Circulation 82:1106-1116, 1990.
PubMed
9) Van Gelder I C, et al:Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 156:2585-2592, 1996.
PubMed
P.159 掲載の参考文献
1) Fuster V, et al:ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 22 (20):1852-1923, 2001.
 
2) Atrial Fibrillation Investigators:Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation:analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449-1457, 1994.
 
3) Hart R G, et al:Antithrombotic therapy to prevent stroke in patients with atrial fibrillation:A meta-analysis. Ann Int Med 131:492-501, 1999.
PubMed
4) SPAFI:The Stroke Prevention in Atrial Fibrillation Study:Final results. Circulation 84:527-539, 1991.
 
5) Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation:Stroke Prevention in Atrial Fibrillation II Study. Lancet 343 (8899):687-691, 1994.
PubMed
6) SPAF Investigators:Warfarin vs. aspirin for prevention of thromboembolism in atrial fibrillation:Stroke Prevention in Atrial Fibrillation II Study. Lancet 343:687-691, 1994.
 
7) Yamaguchi T:Optimal Intensity of Warfarin Therapy for Secondary Prevention of Strokein Patients with Nonvalvular Atrial Fibrillation. A Multicenter, Prospective, Randomized Trial. Stroke 31:817-821, 2000.
 
P.167 掲載の参考文献
1) Jais P, et al:A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 95:572, 1997.
PubMed
2) Haissaguerre M, et al:Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659, 1998.
PubMed
3) Haisaguerre M, et al:Electrophysiological end point for catheter ablation of atrial fibralation initiated from multiple pulmonary venous foci. Circulation 101:1409, 2000.
 
4) Kumagai K, et al:Role of rapid focal activation in the maintenance of atrial fibrillation originating from the pulmonary veins Pacing Clin Electrophysiol 23 (Pt. II):1823, 2000.
 
5) Kumagai K, et al:Eficacy of ablation on different types of atrial fibrillation. Europace 2001:13, 2001.
 
6) Haissaguerre M, et al:Electrophysiological breakthroughs from the left atrium to the pulmonary veins Circulation 1022463, 2000,
 
7) Shah D C, et al:Curative catheter ablation of paroxysmal atrial fibrillation in 200 patients:Strategy for presentations ranging from sustained atrial fibrillation to no arrhythmia PACE 24;1541, 2000
 
8) Oral H, et al:Segrnental ostial ablation to isolate the pulmonary veins during atrial fibrillation feasibility and mechanistic insights. Circulation 106:1256, 2002.
PubMed
9) Tanaka K, et al:A new radiofrequency thermal balloon catheter for pulmonary vein isolation. J Am Con Cardiol 38:2079, 2001.
 
10) Pappone C, et al:Atrial electroanatomical remodeling after circumferential radiofrequency pulmonary vein ablation:Efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 104:2539, 2001.
 
P.175 掲載の参考文献
1) Atrial Fibrillation Follow-up investigation of Rhythm management (AFFIRM) Investigators:A comparison of arte control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833 2000.
 
2) Haissaguerre M, et al:Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 102:2463-2465, 2000.
 
3) Huang D T, et al:Hybrid pharmacologic and ablative therapy. J Cardiovasc Electrophysiol 9:462-469, 1998.
PubMed
4) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators:Preliminary report:Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl JMed 321:406-412, 1989.
 
5) Feld G K, et al:Possible athal proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol 66:378-383, 1990.
 
6) Nabar A, et al:Radiofrequency ablation of"class IC atrial flutter"in patients with resistant atrial fibrillation. Am J Cardiol 83:785-787, 1999.
PubMed
7) Schumacher B, et al:Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhyttmic drugs for atrial fibrillation. Am J Cardiol 83:710-713, 1999.
PubMed
8) Hirao K, et al:Hybrid therapy for atrial fibrillation:Ic-flutter and the doses of Ic-drug. (abstr.) PACE 26:1-S68, 2003.
 
9) Schumacher B, et al:Transverse conduction capabilities of the crista terminalis in patients with atrial flutter and atrial fibrillation. J Am Coll Cardiol 34:363-377, 1999.
PubMed
10) Waldo A L, et al:Spontaneous onset of type I atrial flutter in patients. J Am Coll Cardiol 28:707-712, 1996.
PubMed
11) Waldo A, et al:Mechanisms of atrial flutter and atrial fibrillation:Distinct entities or two sides of a coin? Cardiovasc Res 54:217-229, 2002.
PubMed
12) Stabile G, et al:Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. J Am Coll Cardiol 37:1639-1644, 2001.
PubMed
13) Katritsis D, et al:Ablation therapy of type I atrial flutter may eradicate paroxysmal atrial fibrillation. Am J Cardiol 78:345-347, 1996.
PubMed
14) Natale A, et al:Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency abladtion in patients with atrial flutter. J Am Coll Cardiol 35:1898-1904, 2000.
PubMed
15) Ohmura K, et al:Electrocardiographic and electrophysiologic characteristics of atrial fibrillation organized into atrial flutter by oral administration of class I antiarrhythmic agents. PACE 26:692-702, 2003.
 
16) Tai C T, et al:Persistent atrial flutter in patients treated for atrial fibrillation with amiodaron and propafenon:Electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. J Cardiovasc Electrophysiol 10:1180-1187, 1999.
PubMed
17) Kawabata M, et al:Syncope in patients with atrial flutter during treatment with class IC antiarrhythmic drugs. J EIectrocardiol 34:65-72, 2001.
PubMed
18) Crijns H J, et al:Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. A J Cardiol 62:1303-1306, 1998.
 
19) Reithmann C, et al:Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug-induced atrial flutter. Euro Heart J 24:1264-1272, 2003.
 
P.184 掲載の参考文献
1) Saksena S, et al:Pacing for prevention of tachyarrhythmias. In Clinical cardiac pacing and defibrillation (Elenbogan K A, et al edts), p479-478, WB. Saunders Company, Philadelphia, 2000.
 
2) Anderson H R et al:Long-term follow-up of patients from randomized trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 305 (9086):1210-1216, 1997.
 
3) Gills A M, et al:Randomized crossover comparison of DDDR versus VDD pacing for after atrioventricular junction ablation for prevention of atrial fibrillation. Circulation 102 (2):736-741, 2000.
 
4) Ward K J, et al:Atrial arrhythmia suppression by atrial overdrive pacing. Pacemaker Holter assessment Europace 3 (4):108-114, 2001.
 
5) Israel C W, et al:Atrial pacing in the prevention of paroxysmal atrial fibrillation:First results of a new combined algorithm. PACE 23 (11):1888-1890, 2000.
PubMed
6) Israel C W, et al:The AT-500 Verification Study Investigators:Pace-termination and pacing for prevendon of atrial tachyarrhythmias:results from a multicenter study with an implantable device for atrial therapy. J Cardiovasc Electrophysiol 12 (12):1121-1128, 2001.
 
7) Kale M, et al:Pacemaker prevention therapies for the control of drug-refractory paroxysmal atrial fibrillation. Europace 5 (4) 123-131, 2003.
 
8) Lee M A, et al (for ATTEST investigators):The effect of atrial pacing therapies on atrial tachyarrhythmia burden and frequency. Results of a randomized trial in patients with bradycardia and atrial tachyarrhythmias. J Am Coll Cardiol 41 (11):1926-1932, 2003.
PubMed
9) Bailin S J, et al:Prevention of chronic atrial fibrillation by pacing in the region of Bachmann's bundle. J Cardiovasc Electrophysiol 12 (8):912-917, 2001.
 
10) Padeletti L, et al:Randomized crossover comparison of right atrial appendage pacing versus intraatrial septum pacing for prevention of paroxysmal atrial fibrillation in patients with sinus bradycardia. Am Heart J 142 (6):1047-1055, 2001.
 
11) D'Allonnes G R, et al:Long-term effects of biatrial synchronous pacing to prevent drug-refractory atrial tachycardia:A nine-year experience. J Cardiovasc Electrophysiolo 11 (10):1081-1091, 2000.
PubMed
12) Mirza I, et al:Biatrial pacing for prevention for paroxysmal atrial fibrillation. A randomized prospective study into the suppression of paroxysmal atrial fibrillation using biatrial pacing. J Am Coll Cardil 40 (3):457-463, 2002.
 
13) Delfault P, et al:Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single-and dual site right atrial pacing for arrhythmia prevention. J Am Coll Cardiol 32 (7):1900-1908, 1998.
PubMed
14) Lau C P, et al:Dual-site atrial pacing for atrial fibrillation in patients without bradycardia. Am J Cardiol 88 (2):371-375, 2001.
PubMed
15) Saksena S, et, al:Improved suppression of recurrent atrial fibrillation with dual-site atrial pacing and antiarrhythmic drug therapy. J Am Con Cardiol 40 (6):1140-1150, 2002.
 
16) Gill A M, et al (for GEM III AT Worldwide Investigators):Safety and efficacy of advanced atrial pacing therapies for atrial tachyarrhythmias in patients with a new implantable dual chamber cardioverter-defibrillator. J Am Coll Cardiol 40 (9):1653-1659, 2002.
 
17) Wood M A, et al:Clinical outcomes after ablation and pacing therapy for atrial fibrillation. A meta-analysis. Circulation 101 (3):1138-1144, 2000.
PubMed
18) Daoud E G, et al:Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 78 (12):1433-1436, 1996.
PubMed
19) Geelen P, et al:Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. PACE 20 (2):343-348, 1997.
 
20) Wyse D G, et al (AFFIRM Investigators):A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (23):1825-1833, 2002.
 
P.195 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (1999-2000年度合同研究班報告) 不整脈の非薬物治療ガイドライン. Jpn Circ J 65(Suppl. V):1127-1175, 2001.
 
2) Bando K, et al:Impact of Cox maze procedure on outcome in patients with atrial fibrillation and mitral valve disease. J Thorac Cardiovasc Surg 124:575-583, 2002.
 
3) Cox J L, et al:Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg 118:833-840, 1999.
PubMed
4) Nitta T, et al:Radial approach:A new concept in surgery for atrial fibrillation. 2. Electrophysiological effects and atrial contribution to ventricular filling. Ann Thorac Surg 67:36-50, 1999.
 
5) Ishii Y, et al:Serial change in the atrial transport function after the radial incision approach. Ann Thorac Surg 71:572-576, 2001.
PubMed
6) Sueda T, et al:Simple left atrial procedure for chronic atrial fibrillation associated with mitral valve disease. Ann Thorac Surg 62:1796-1800, 1996.
PubMed
7) Sueda T, et al:Efficacy of pulmonary vein isolation for the elimination of chronic atrial fibrillation in cardiac valvular surgery. Ann Thorac Surg 71:1189-1193, 2001.
PubMed
8) Nitta T, et al:Concurrent multiple left atrial focal activations with fibrillatory conduction and right atrial focal or reentrant activation as the mechanism in atrial fibrillation. J Thorac Cardiovasc Surg (in press).
PubMed
9) Prasad S M, et al:Chronic transmural atrial ablation by using bipolar radiofrequency energy on the beating heart. J Thorac Cardiovasc Surg 124:708-713, 2002.
 
P.203 掲載の参考文献
1) 厚生省循環器病委託研究班:公開シンポジウム「循環器病治療とQuality of life」. Ther Res 11:2433-2494, 1990.
 
2) 萱場一則:高齢者循環器疾患患者の QOL に影響する背後因子. Ther Res 14:3318-3322, 1993.
 
3) Croog S E, et al:The effect of antihypertensive thrapy on the quality of life. N Engl J Med 314:1657-1664, 1986.
 
4) Siegrist J:Impaired quality of life as a risk factor in cardiovascular disease. J Chronic Dis 40:571-578, 1987.
PubMed
5) 笠貫 宏, 他:心房細動患者におけるストレスと QOL 心房細動, 粗動, 頻拍 (早川弘一, 他 編), p66-73. 医学書院, 東京, 1999.
 
6) Jenkins L S, et al:Quality of life in patients with atrial fibrillation. Cardiol Clin 14:597-606, 1996.
PubMed
7) 鈴木伸一, 他:発作性および慢性心房細動患者における基礎疾患の有無からみた QOL および発作不安の検討. 第51回循環器心身医学会会合記録:9-11, 1997.
 
8) Suzuki S, et al:The Influences of psychosocial aspects and anxiety symptoms on quality of life of patients with arrhythmia:Investigation in paroxysmal atrial fibrillation. International Journal of Behavior Medicine (In press)
 
9) 鈴木伸一, 他:発作性心房細動患者の QOL 発作への不安, および外出恐怖に及ぼす自覚的発作症状の影響. 心身医 40:603-610, 2000.
Medical*Online
10) 世界保健機構精神保健と薬物乱用予防部, 編:WHO/QOL- 26 手引. 金子書房, 東京, 1997.
 
11) 福原俊一, 他:SF-36 日本語マニュアル Ver.1.2. (財) パブリックヘルスリサーチセンター, 東京, 2001.
 
12) 笠貫 宏:ICD の現状と問題点. 不整脈 News & Views, 11, 1996.
 
P.210 掲載の参考文献
1) 野村 忍:循環器疾患における心身医学. 循環器 42:392-396, 1997.
 
2) 小此木啓吾:精神療法を行う医師. 心身症診療 Q&A (小此木啓吾, 他編), p436-441, 六法出版, 大阪, 1984.
 
3) 中尾睦宏, 他:血圧バイオフィードバック療法の現状とその将来:Evidence-Based Medicine の見地から. 心身医 43:221-231, 2003.
Medical*Online
P.218 掲載の参考文献
1) 杉本恒明:心房細動の疫学 (早川弘一, 他 編), p14-18 東京, 医学書院, 1999.
 
2) Lip GYH:Patholophysiology of atrial fibrillation:haemodynamics, thromboembolic risk, hypercoagulability. In:atrial fibrillation in clinical practice, p65-74. Martin Dunitz, London, 2001.
 
3) Jais P, et al:Left ventricular diastolic dysfunction in patients with so-called lone atrial fibrillation. J Cardiovasc Electrophysiol 11:623-625, 2000.
PubMed
4) Thamilarasan M, et al:Left ventricular diastolic dysfunction in lone atrial fibrillation determined by Doppler tissue imaging of mitral annular motion. Am J Cardiol 86:1026-1029, 2000.
PubMed
5) Packer D L, et al:Tachycardia-induced cardiomyopathy:a reversible form of left ventricular dysfunction. Am J Cardiol 57:563-570, 1986.
PubMed
6) Wijffels M C E F, et al:Atrial fibrillation begets atrial fibrillatiorr A study in awake chronically instrumented goats. Circulation 92:1954-1968, 1995.
 
7) Allessie M, et al:Electrophysiological mechanisms of atrial fibrillation. In:Atrial arrhythmias. State of the art (DiMarco Jp, et al eds), p155-161. Futura, Armonk, 1995.
 
8) Yue L, et al:Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 81:512-525, 1997.
 
9) Daoud E G, et al:Effect of verapamil and procainarnide on atrial fibrillation-induced electrical remodeling in humans. Circulation 96:1542-1550, 1997.
PubMed
10) Lee S-H, et al:Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation 101:200-206, 2000.
PubMed
11) Stoddard M F, et al:Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event:a transesophageal echocardiographic study. J Am Con Cardiol 25:452-459, 1995.
 
12) Fatkin D, et al:Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation:Evidence for"atrial stunning"as a mechanism of thrombolic complications. J Am Coll Cardiol 23:307-316, 1994.
 
13) More R S, et al:Lone atrial fibrillation and anticoagulant therapy. Clin Cardiol 16:504-506, 1993.
PubMed
14) 杉薫, 他:心房細動例における脳梗塞の発症頻度. 心電図 19:12-19, 1999.
 
15) Kirchhof P F, et al:Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs. Antiarrhythmic and proarrhythmic effects. Circulation 97:2567-2574, 1998.
 
16) Atarashi H, et al:Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide. Am J Cardiol 78:694-697, 1996.
PubMed
17) 川瀬綾香, 他:発作性心房細動の洞調律維持に対するIII群薬の効果-アミオダロン, ソタロール, ベプリジルの比較-. Prog Med 21 (Suppl 1):1180-1183, 2001.
 
18) Weerasooriya R, et al:The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT). Am J Coll Cardiol 41:1697-1702, 2003.
 
19) Pappone C, et al:Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation. Am J Coll Cardiol 42:185-197, 2003.
 
20) Hart R G, et al:Antithrombotic therapy to prevent stroke in patients with atrial fibrillation:Ameta-analysis. Ann Intern Med 131:492-501, 1999.
 
21) Yamaguchi T:Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. A multicenter, prospective, randomized trial. Stroke 31:817-821, 2000.
PubMed
P.229 掲載の参考文献
1) Feinberg WM, et al:Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 155:469-473, 1995.
PubMed
2) Atrial Fibrination Investigators:Risk factors for stroke and efficacy of antithrombotic therapy in atrial Fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449-1457, 1994.
 
3) SPAF investigators:Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation:Stroke Prevention in Atrial Fibrillation II Study. Lancet 343:687-691, 1994.
 
4) Yamaguchi T:Optimal intensity of warfarin therapy for sccondary prevention of stroke in patients with nonvalvular atrial fibrillation:a multicenter, prospective, randomized trial Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 31:817-821, 2000.
 
5) SPAF investigators:Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation:Stroke Prevention in Atrial Fibrillation III randomised clinical triaL Lancet 348:633-638, 1996.
 
6) Caraballo p J, et al:Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 159 (15):1750-1756, 1999.
PubMed
P.236 掲載の参考文献
1) Dries D L et al:Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with a symptomatic and symptomatic left ventricular dysfunction:A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 32:695-703, 1998.
PubMed
2) Flaker G C, et al:Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation:The Stroke Prevention in Atrial Fibrillation investigators. J Am Coll Cardiol 20:527-532, 1992.
PubMed
3) Volgman A S et al:Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 31:1414-1419, 1998.
PubMed
4) Shiga T, et al:Antiarrhythmic effect of nifekalant on atrial tachyarrhythmia in four patients with severe heart failure. J Cardiol 39:159-164, 2002.
PubMed
5) Singh B N:Current antiarrhythmic drugs:An overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol 10:283-301, 1999.
PubMed
6) Prystowsky E N:Management of atrial fibrillation:Therapeutic options and clinical decisions. Am J Cardiol 85:3D-11D, 2000.
PubMed
7) Roy D, et al:for the Canadian Trial of Atrial Fibrillation investigators:Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342:913-920, 2000.
 
8) Shiga T, et al:Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. Circ J 66:600-604, 2002.
 
9) Doval H C, et al:for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA):Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 344:493-498, 1994.
 
10) Massie B M, et al for the CHF-STAT Investigators:Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 93:2128-2134, 1996.
PubMed
11) Deedwania P C, et al, for the Department of Veterans Affairs CHF-STAT Investigators:Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation:Observation from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 98:2574-2579, 1998.
PubMed
12) Torp-Pedersen C, et al:Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 341:857-865, 1999.
PubMed
13) Pedersen O D, et al:Efficacy of dofetilide in the treatment of atrial fibrillation flutter in patients with reduced left ventricular function:a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 104:292-296, 2001.
PubMed
14) The Digitalis Investigation Group:The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525-533, 1997.
 
15) Radonale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure:the Atrial Fibrillation and Congestive Heart Failure (AFLCHF) trial. Am Heart J 144:597-607, 2002.
PubMed
16) Nakashima H, et al:Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 101:2612-2617, 2000.
PubMed
P.244 掲載の参考文献
1) Klein G J, et al:Ventricular fibrillaton in the Wolff-Parkinson-White syndrome. N Engl J Med 301:1080-1085, 1979.
 
2) Wellens H J J, et al:Wolff-Parkinson-White syndrome and atrial fibrillation. Relation between refractory period of accessory pathway and ventricular rate during atrial fibrillation. Am J Cardiol 34:777-782, 1974.
 
3) Satoh M, et al:Electrophysiologic evalution of a symptomatic patients with the Wolff-Parkinson-White pattern Pace 12:413-420, 1989.
 
4) Bendit D G, et al:Enhanced atrioventricular conduction in patients without preexcitation syndrome. Relation to heart rate in paroxysmal reciprocating tachycardia. Circulation 65:1474, 1982.
 
5) Robinson K, et al:Atrial fibrillation in hypertrophic cardiomyopathy. JACC 15:1279-1285, 1990.
PubMed
6) Yano M, et al:FKBP 12.6-mediated stabihzation of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 107:477-484, 2003.
 
7) Benjaminn E J, et al:Impact of atrial fibrillation on the risk of death. The Framinghamstudy. Circulation 98:946-952, 1998.
 
8) Deedwania P C, et al:Spontaeous conversion and maintenance of sinus rhythm byamiodarone in patients with heart failure and atrial fibrillation. Observation from the Veteran Affairs Congestive Hearet Failure Survival Trails of Antiarhythmic Therapy (CHF-STAT). Circulation 98:2527-2579, 1998.
 
9) MERIT-HF Group:Effect of metoprorol CR/XL in chronic heart failure:Metprorol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001-2007, 1999.
 
10) Singh B N:Controlling cardiac arrhythmias:an overview with a historical perspective Am J Cardiol 80:4G-15G, 1997.
PubMed
11) Flaker G C, et al:Antiarrhythmic drug therapy and cardiac mortahty in atrial fibrillation:The stroke prevention in atrial fibrillation investigators. JACC 20:527-532, 1992.
PubMed
12) Prystowsky E N, et al:Management of patients with atrial fibrillation. A statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology., American Heart Association. Circulation 93:1262-1277, 1996.
PubMed
P.260 掲載の参考文献
1) Kannel W B, et al:Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation:population-based estimates. Am J Cardiol 82 (Suppl 8A):S2-9, 1998.
 
2) 久道 茂:医学判断学入門. 南江堂, 東京, 1990.
 
3) Naglie I G, et al:Treatment of chronic nonvalvular atrial fibrillation in the elderly:A decision analysis. Med Decis Making 12:239-249, 1992.
PubMed
4) 井上忠夫:臨床判断分析に関する文献の批判的吟味 (2) 臨床判断分析の応用-マルコフモデルの文献をどう読むか-. 薬の知識 52:104-108, 2001.
 
5) Gage B F, et al:Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvascular atrial fibrillation. JAMA 274:1839-1845, 1995.
 
6) Stroke prevention in atrial fibrillation investigators:Warfarin vs aspirin for prevention of thromboembolism in atrial fibrillation:Strokein Atrial Fibrillation II Study. Lancet 343:687-691, 1994.
 
7) Boysen P P, et al:Placebo controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complication inchronic atrial fibrillation. The Copenhagen AFASAK study. Lancet I:175-179, 1989.
 
8) The research group for antiarrhythmic drug therapy:Cost-effectiveness of antiarrhythmic drugs for prevention of thromboembolism in patients with paroxysmal atrial fibrillation. Jpn Circ J 65:765-768, 2001.
 
P.267 掲載の参考文献
1) Marban E:Cardiac channelopathy. Nature 415:213-218, 2002.
PubMed
2) Wijffels MCEE et al:Atrial fibrillation begets anial fibrillation. A study in awake chronically instrumented goats. Circulation 92:1954-1968, 1995.
 
3) Yamashita T, et al:Short-term effects of rapid pacing on the mRNA levels of voltage-dependent K? channels in the rat atrium:electrical remodeling in paroxysmal atrial tachycardia. Circulation 101:2007-2014, 2000.
PubMed
4) Nattel S, et al:Ionic remodeling in the heart:pathophysiological significance and new therapeutic opportunities in atrial fibrillation. Circ Res 87:440-447, 2000.
PubMed
5) Li D, et al:Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 101:2631-2638, 2000.
PubMed
6) Goette A, et al:Increased expression of extracellular signal-related kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35:1669-1677, 2000.
PubMed
7) Pedersen O D, et al:Trandrapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:376-380,1999.
PubMed
8) Vermes E, et al:Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction:insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials Circulation 107:2926-2931, 2003.
PubMed
9) Roy D, et al:Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation lnvestigators. N Engl J Med 342 (13):913-920, 2000.
PubMed
P.276 掲載の参考文献
1) AFFIRM investigators:A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833, 2002.
 
2) Van Gelder I C, et al:A Comparison of Rate control and Rhythm Control in patients with recurrent Persistent Atrial Fibrillation. N Engl J Med 347:1834-1840, 2002.
PubMed
3) 外山淳治, 他:心房細動治療(薬物)ガイドライン. Jpn Circ J 65 (Supple V):931-998, 2001,
 
4) Rawles J M:What is meant by a"controlled" ventlictricural rate in atrial fibrilation? Br Heart J 63:157-161, 1990.
PubMed
5) Page R L:A symptomatic arrythmias in patients with symptomatic paroxysmal atrial fibrillation and proxysmal supraventricular tachycardia. Circulation 89:224-227, 1994.
 
6) Fetsch T, et al:How reliable are symptoms for detection of atrial fibrillation in crinical routin? Results of the PAFAC trial. Eur Heart J 4 (suppl):662, 2002.
 
P.285 掲載の参考文献
1) Wellens HJJ, et al:Atrioverter:an implantable device for the treatment of ac fibrillation. Circulation 98:1651-1656, 1998.
 
2) Daoud E G, et al:Initial clinical experience with ambulatory use of an implantable atrial debillator for conversion of atrial fibrillation. Circulation 102:1407-1413, 2000.
PubMed
3) Schoels W, et al:Worldwide clinical experience with a new dual-chamber implantable cardioverte defibrillator sytem. J Cardiovasc Electrophysiol 12:521-528, 2001.
 
4) Gold M R, et al:Clinical experience with a dual-chamber implantable cardioverter defibrillato to treat atrial tachyarrhythrnias J Cardiovasc Electrophysiol 12:1247-1253, 2001.
 
5) Tse H F, et al:Atrial fibrillation detection and R-wave synchronization by Metrix implantale atrial defibrillator:Implications for long-term efficacy and safety. Circulation 99:1446-1451, 1999.
 
6) Dijkman B, et al:Dual chamber arrhythmia detection in the implantable cardioverter defibrilltor. J Cardiovasc Electrophysiol 11:1105-1115, 2000.
PubMed
7) Swerdlow C D, et al:Detection of atrial fibrillation and flutter by a dual-chamber implantable cardioverter defibrillator. Criculation 101:878-885, 2000.
 
8) Adler S W, et al:Efficacy of pacing therapies for treating atrial tachyarrhythmias in patients with ventricular arrhythmias receiving a dual-chamber implantable cardioverter defibrillator. Circulation 104:887-892, 2001.
PubMed
9) Friedman P A, et al:Atrial therapies reduce atrial arrhythmia burden in defibrillator patients. Circulation 104:1023-1028, 2001.
PubMed
10)Friedman P A, et al:Atrial therapies reduce atrial arrhythmia burden in defibrillator patients. Circulation 104:1023-1028, 2001.
PubMed
11) Tieleman R G, et al:Early recurrences of atrial fibrillation after electrical cardioversion:a result of fibrillation induced electrical remodeling of the atria? J Am Coll Cardiol 31:167-173, 1998.
 
12) Sopher S M, et al:Atrial fibrillation:Maintenance of sinus rhythm versus rate control. Am J Cardiol 77:24A-37A, 1996.
PubMed
13) Marchlinski F E, et al:The automatic implantable cardioverter-defibrillator:efficacy, complications and device failures. Ann Intern Med 104:481-490, 1986.
PubMed
14) Harbinson M T, et al:Rounded biphasic wave-form reduces energy requirements for transvenous catheter cardioversion of atrial fibrillation and atrial flutter. Pacing Clin Electrophysiol 20:226-229, 1994.
 
15) Newman D M, et al:Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. Am Heart J 145 (5):841-846, 2003.
PubMed
16) Ware J E, et al:The MOS 36-Item Short-Form Health Survey (SF-36) I:conceptual framework and item slection. Medical Care 30:473-483, 1992.
 
17) Jenkins L S, et al:Quality of life in patients with symptomatic atrial fibrillation Circulation 92 (8):I-490, 1995.
 
18) Griffin JC, et al:Is the automatic atrial defibrillator a promising approach? J Cardiovasc Electrophysiol:1217-1224, 1996.
PubMed

第5章 心房細動のガイドライン

P.291 掲載の参考文献
1) 外山淳治, 他:心房細動治療(薬物)ガイドライン. Jpn Circulation J 65 (suppl V):931-998, 2001.
 
2) Haissaguerre M:Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 7:1132-1144, 1996.
PubMed
3) 松浦昭雄 他:心房細動の非薬物療法-左房 mage を中心として-. (山田和生監, 伊藤昭雄, 他編):心房細動の最近の話題. p75-80. ライフメデイコム, 名古屋, 1999.
 
4) Fuster V, et al:ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation:execuive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). Circulation 104:2118-2150, 2001.
 
5) 瀬川郁夫:心房細動の静注薬治療. 救急現場における不整脈治療-アンケートをもとに-. 不整脈診療 3:1-3, 2002.
 

書評

最近チェックした商品履歴

Loading...